Last reviewed · How we verify
Oral prednisolone Taper
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, polymyalgia rheumatica), Allergic reactions and asthma exacerbations, Adrenal insufficiency.
At a glance
| Generic name | Oral prednisolone Taper |
|---|---|
| Also known as | Prednisone |
| Sponsor | Berinstein, Jeffrey |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General inflammation |
| Phase | FDA-approved |
Mechanism of action
Prednisolone exerts its anti-inflammatory and immunosuppressive effects by entering cells and binding to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. A taper regimen gradually reduces the dose to allow the hypothalamic-pituitary-adrenal (HPA) axis to recover normal endogenous cortisol production.
Approved indications
- Inflammatory and autoimmune conditions (e.g., rheumatoid arthritis, lupus, vasculitis)
- Allergic reactions and asthma exacerbations
- Adrenal insufficiency
- Certain hematologic and oncologic conditions
Common side effects
- Insomnia
- Increased appetite
- Mood changes (irritability, anxiety)
- Hyperglycemia
- Hypertension
- Osteoporosis (with chronic use)
- Immunosuppression / increased infection risk
- Gastrointestinal upset
Key clinical trials
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
- Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral prednisolone Taper CI brief — competitive landscape report
- Oral prednisolone Taper updates RSS · CI watch RSS
- Berinstein, Jeffrey portfolio CI